share_log

Capital One Initiates Coverage On Heron Therapeutics With Overweight Rating, Announces Price Target of $6

Moomoo 24/7 ·  Apr 23 07:14

Capital One analyst Tim Chiang initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Overweight rating and announces Price Target of $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment